SCOLR Pharma, Inc. (DDD) Announces The Start Of Its Extended Release CDT-Pseudoephedrine Human Trials
10/19/2005 5:12:52 PM
BELLEVUE, Wash.--(BUSINESS WIRE)--March 1, 2005--SCOLR Pharma, Inc. (Amex:DDD) announced today that it has initiated human testing of its 12-hour Controlled Delivery Technology (CDT(R))-based pseudoephedrine tablets. The first of three planned U.S. studies was started on February 26, 2005. These studies are intended to support an anticipated Abbreviated New Drug Application submission to the Food and Drug Administration this summer.
SCOLR Pharma had previously announced an agreement with UPM Pharmaceuticals for the manufacture of the pseudoephedrine tablets to be used in these human trails. This is the Company's second CDT-based formulation designed for the U.S. OTC (over-the-counter) market, the first being ibuprofen.